Possible risk for cardiac arrhythmia related to intravenous erythromycin
- 1 August 1992
- journal article
- case report
- Published by Springer Nature in Intensive Care Medicine
- Vol. 18 (8) , 469-473
- https://doi.org/10.1007/bf01708583
Abstract
To evaluate the incidence of prolongation of the rate-corrected electrocar diographic QT interval (QTc) and of ventricular arrhythmia associated with intravenous administration of erythromycin lactobionate.Keywords
This publication has 12 references indexed in Scilit:
- [QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant].1991
- Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanismThe American Journal of Medicine, 1990
- Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).BMJ, 1990
- AN ELECTROPHYSIOLOGICAL STUDY OF THE ARRHYTHMOGENIC EFFECTS OF ERYTHROMYCIN1988
- Arrêt circulatoire peropératoire après injection intraveineuse de lactobionate d'érythromycineAnnales Françaises dʼAnesthésie et de Réanimation, 1988
- ErythromycinMedical Clinics of North America, 1987
- Torsades de pointes associated with drugs and toxins: Recognition and managementAmerican Heart Journal, 1987
- Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndromeThe American Journal of Cardiology, 1987
- QT prolongation and recurrent “torsades de pointes” during erythromycin lactobionate infusionThe American Journal of Cardiology, 1986
- Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycinThe American Journal of Cardiology, 1984